Andrew D. Krystal: research papers - The Consciousness Library

The Case for More Aggressive Masking in Psychedelic Trials

JAMA Psychiatry September 16, 2026 Kevin H. Yang, Boris D. Heifets, Andrew D. Krystal et al.

This Viewpoint discusses the UMBRAA (unidentifiable multidrug blinding with reduced, authorized awareness) strategy to address the masking problem in psychedelic trials.

DOI: 10.1001/jamapsychiatry.2026.2858

Treatment Expectancies and Psilocybin vs Escitalopram for Depression

JAMA Psychiatry December 10, 2024 Ethan G. Dutcher, Andrew D. Krystal 5 citations

This secondary analysis of a randomized clinical trial examines the association between treatment expectancies and the relative efficacy of psilocybin compared with escitalopram for major depressive disorder.

DOI: 10.1001/jamapsychiatry.2024.4387 Full text Psilocybin Anxiety Escitalopram Depression economics +3

A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?

Psychedelic Medicine February 28, 2024 Joshua Woolley, Amanda E. Downey, Ellen Bradley et al. 2 citations

Balancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family history of BD, we argue for caution in psychedelic clinical trials but not outright exclusion of these individuals. Our risk stratification tool allows for more nuanced inclusion and exclusion criteria.

DOI: 10.1089/psymed.2023.0051 Full text Psilocybin Bipolar disorder Plea Psychotherapist +2

Papers

The Case for More Aggressive Masking in Psychedelic Trials

Treatment Expectancies and Psilocybin vs Escitalopram for Depression

A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?